SuperSonic Imagine Reports Sales Growth of +13% in Q3 2017 (+16% at Constant Currency)

Regulatory News:

SuperSonic Imagine (Euronext: SSI, FR0010526814, PEA-PME eligible) (Paris:SSI), a company specializing in ultrasound medical imaging, today announces its sales for the third quarter to September 30, 2017.

Unaudited data
(*) these revenues are non recurrent by nature and are not part of the Company’s core business.

SuperSonic Imagine has recorded a fifth straight quarter of double-digit growth. In the 3^rd quarter of 2017, the Company generated growth of +13% to €6.45 million compared with the 3^rd quarter of 2016. At constant currency, growth was +16%.
The Company is continuing its solid growth momentum in Product sales, which increased by +10% to €5.68 million (vs. €5.18 million). At constant currency, this growth was +12%. Service sales jumped +48% to €766 thousand (vs. €519 thousand) and accounted for 12% of quarterly sales.

On our priority markets, over the quarter China and France recorded growth of +96% to €2.07 million (vs. €1.05 million) and +32% to €1.28 million (vs. €966 thousand) respectively. The United States saw sales decrease by 45% to €704 thousand (vs. €1.28 million) as the headcount was less than the previous year and the recruitment and ramp-up took longer than expected for replacement personnel.. This decrease confirms that the US Sales & Marketing team is not yet sufficiently staffed. The Company intends to intensify its efforts in this key market and to ensure a return to long-term growth.

Over this 3^rd quarter, these priority markets recorded growth of 23%, with sales totalling €4.05 million (vs. €3.3 million), or 63% of total sales. More globally, Asia and EMEA grew by +43% to €2.81 million (vs. €1.96 million) and +18% to €2.72 million (vs. €2.30 million), respectively.

Altogether over the first nine months of the year, SuperSonic Imagine generated growth of +15% to €16.74 million (vs. €14.55 million). Product sales totalled €14.71 million (vs. €13.04 million), giving growth of +13%, while Service sales increased by +34% to €2.03 million (vs. €1.52 million).

Therefore, at end-September 2017, China reaffirmed its buoyant growth (+52% to €5.24 million vs. €3.44 million), as did France (+23% to €3.53 million vs. €2.88 million), while the United States recorded a fall (-26% to €2.05 million vs. €2.78 million). Together, these three priority markets generated solid growth of +19% to €10.81 million (vs. €9.09 million). Across all regions, Asia and EMEA grew by +32% to €6.97 million (vs. €5.28 million) and +21% to €7.44 million (vs. €6.16 million) respectively.

Taking into account other revenue, essentially consisting of non-recurrent fees to access the Group’s technology, over the first nine months of 2017 SuperSonic Imagine recorded total revenues of €16.74 million, up 7% compared with the same period of 2016.

Michèle Lesieur, CEO and President of SuperSonic Imagine, comments: "I am pleased with the revenue we recorded over the third quarter that have given us our fifth quarter of double-digit growth in a row. It should be noted that, over the quarter, the impact of the euro’s strengthening against the US dollar was significant. China and France have been our two main growth drivers since the start of the year, while the decrease observed in the United States confirms that we need to strengthen our Sales & Marketing presence there in order to reverse this trend. This third quarter also saw the launch of our new "Aixplorer Ultimate” product, which has 4.5 times the computing power of previous models and has a new design and new user interface. Initial reaction to this new product from our clients has been extremely positive, and strengthens our belief in the Company’s bright future.”

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer^®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler, Angio PL.U.S – Planewave UltraSensitive™ Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171018005803/en/